Zynex: Deteriorating Fundamentals and Signs of Reimbursement Pressure – Night Market Research

Price: $ 50.99

4.7(256)

Revenue growth masks deteriorating profitability: operating margins trend lower (64% lower past two years) as Zynex accelerates hiring in face of early signs of reimbursement pressure. Tricare becomes first large health plan since Medicare to drop ZYXI’s device for one of its largest indications citing poor efficacy - we expect other payors to follow Zynex…

https://static.seekingalpha.com/uploads/2019/10/20/49229281-1571608013029258_origin.png

Zynex: Abusive Pricing Model Unsustainable (NASDAQ:ZYXI)

https://static.seekingalpha.com/uploads/2019/10/20/49229281-15716089963189094_origin.png

Zynex: Abusive Pricing Model Unsustainable (NASDAQ:ZYXI)

https://static.seekingalpha.com/uploads/2019/10/20/49229281-15716142188089502_origin.png

Zynex: Abusive Pricing Model Unsustainable (NASDAQ:ZYXI)

https://images.squarespace-cdn.com/content/v1/535bcb2fe4b05fe61b320c51/85fa6e00-ecd6-459e-8e31-8ce363381b07/image9.png

PRECISION Targeting in Resistant Hypertension — NephJC

https://cdn.kscope.io/8a668634fa7f14f6218f8dd18db594e2-ghjrgll3j20m000035.jpg

SEC Filing

https://imgcdn.mckesson.com/CumulusWeb/Images/Original_Image/204192_pdet.jpg

Precision Dynamics 15035-11-MGD - McKesson Medical-Surgical

https://cdn.kscope.io/28a50339484e57048d0277957ed5e1df-g158977dsp019.jpg

SEC Filing Terns Pharmaceuticals, Inc.

https://static.seekingalpha.com/uploads/2021/12/7/49229281-1638933295853874_origin.png

Zynex: Turnaround Nears End – UnitedHealthcare Cuts TENS

https://medlearnpublishing.s3.us-east-2.amazonaws.com/wp-content/uploads/unemployed-man-with-empty-pockets-due-to-coronavirus-economic-impact-e1668143597669-1536x1025.jpg

Radiology Reimbursement on the Rocks: Decade's Research Shows